Despite the success of the available polysaccharide-based vaccines against Streptococcus pneumoniae in preventing invasive diseases, this bacterium remains a major cause of death in many parts of the world. New vaccine strategies are needed in order to increase protection. Thus, the utilization of fusion proteins is being investigated as an alternative to the current formulations. In the present work, we demonstrate that a chimeric protein, composed of PspA and PotD in fusion is able to maintain the protective characteristics of both parental proteins, providing protection against systemic infection while reducing nasal colonization. The hybrid was not able to improve the response against invasive disease elicited by PspA alone, but the inc...
Protein bodies (PBs) are particles consisting of insoluble, aggregated proteins with potential as a ...
Respiratory tract infections and invasive disease caused by Streptococcus pneumoniae in high-risk gr...
A promising alternative vaccine candidate to reduce the burden of pneumococcal diseases is the prote...
© 2017 Elsevier Ltd Despite the success of the available polysaccharide-based vaccines against Strep...
PspA and pneumolysin are two important vaccine candidates, able to elicit protection in different mo...
Pneumococcal surface protein A (PspA) and Pneumolysin derivatives (Pds) are important vaccine candid...
<div><p>Pneumococcal surface protein A (PspA) and Pneumolysin derivatives (Pds) are important vaccin...
Pneumococcal surface protein A (PspA) and Pneumolysin derivatives (Pds) are important vaccine candid...
PMCID: PMC1828427Current global efforts are focused on exploring alternative pneumococcal vaccine st...
Current pneumococcal vaccines are composed of capsular polysaccharides (PS) of various serotypes, ei...
Pneumococcal surface protein A (PspA) is highly immunogenic and can induce a protective immune respo...
Pneumococcal surface protein A (PspA) is a widely studied pneumococcal protein, exposed at the surfa...
© 2017 Elsevier Ltd Pneumococcal surface protein A (PspA) is a widely studied pneumococcal protein, ...
Pneumococcal surface protein A (PspA), a cross-reactive protein expressed by all pneumo-cocci, is kn...
The Gram-positive bacterium Streptococcus pneumoniae(pneumococcus) is a major human pathogen, causin...
Protein bodies (PBs) are particles consisting of insoluble, aggregated proteins with potential as a ...
Respiratory tract infections and invasive disease caused by Streptococcus pneumoniae in high-risk gr...
A promising alternative vaccine candidate to reduce the burden of pneumococcal diseases is the prote...
© 2017 Elsevier Ltd Despite the success of the available polysaccharide-based vaccines against Strep...
PspA and pneumolysin are two important vaccine candidates, able to elicit protection in different mo...
Pneumococcal surface protein A (PspA) and Pneumolysin derivatives (Pds) are important vaccine candid...
<div><p>Pneumococcal surface protein A (PspA) and Pneumolysin derivatives (Pds) are important vaccin...
Pneumococcal surface protein A (PspA) and Pneumolysin derivatives (Pds) are important vaccine candid...
PMCID: PMC1828427Current global efforts are focused on exploring alternative pneumococcal vaccine st...
Current pneumococcal vaccines are composed of capsular polysaccharides (PS) of various serotypes, ei...
Pneumococcal surface protein A (PspA) is highly immunogenic and can induce a protective immune respo...
Pneumococcal surface protein A (PspA) is a widely studied pneumococcal protein, exposed at the surfa...
© 2017 Elsevier Ltd Pneumococcal surface protein A (PspA) is a widely studied pneumococcal protein, ...
Pneumococcal surface protein A (PspA), a cross-reactive protein expressed by all pneumo-cocci, is kn...
The Gram-positive bacterium Streptococcus pneumoniae(pneumococcus) is a major human pathogen, causin...
Protein bodies (PBs) are particles consisting of insoluble, aggregated proteins with potential as a ...
Respiratory tract infections and invasive disease caused by Streptococcus pneumoniae in high-risk gr...
A promising alternative vaccine candidate to reduce the burden of pneumococcal diseases is the prote...